Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04887870 | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | PHASE2 | COMPLETED | 52 | — | — | Jun 29, 2021 | Sep 25, 2025 | Oct 10, 2025 | 13 | United States |
| Arm | Type | Description |
|---|---|---|
| Phase 2/3: Open label extension of parent study | EXPERIMENTAL | The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial. |
| Name | Type | Description |
|---|---|---|
| Sitravatinib | DRUG | Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases. |
| Nivolumab | DRUG | Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody |
| Pembrolizumab | DRUG | Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody |
| Enfortumab Vedotin-Ejfv | DRUG | Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) |
| Ipilimumab | DRUG | Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody |
Inclusion Criteria: * Currently receiving sitravatinib single- agent or in combination with other therapeutic agent(s) in another Mirati- sponsored protocol * Currently tolerating the treatment regimen in the parent protocol * Experiencing clinical benefit with or without prior radiographic progres...